Calcium and phosphorus regulatory hormones and risk of incident symptomatic kidney stones

Clinical Journal of the American Society of Nephrology

Volumn 10, Issue 4, 2015, Pages 667-675

  Taylor, Eric N ^a,b   Hoofnagle, Andrew N ^c   Curhan, Gary C ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MAINE MEDICAL CENTER   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

24,25 DIHYDROXYVITAMIN D; 25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; CALCIUM OXALATE; CALCIUM PHOSPHATE; CALCIUM REGULATORY HORMONE; CREATININE; FIBROBLAST GROWTH FACTOR 23; HORMONE; PARATHYROID HORMONE; PHOSPHATE; PHOSPHORUS REGULATORY HORMONE; UNCLASSIFIED DRUG; 1,25-DIHYDROXYVITAMIN D; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; PHOSPHORUS; VITAMIN D;

ADULT; AGED; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CALCIUM INTAKE; CASE CONTROL STUDY; CONTROLLED STUDY; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; FOOD FREQUENCY QUESTIONNAIRE; HEMATURIA; HORMONE BLOOD LEVEL; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; NEPHROLITHIASIS; PROSPECTIVE STUDY; RISK ASSESSMENT; ANALOGS AND DERIVATIVES; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; INCIDENCE; KIDNEY CALCULI; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; UNITED STATES;

ADULT; AGED; BIOMARKERS; CALCIUM; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FIBROBLAST GROWTH FACTORS; HORMONES; HUMANS; INCIDENCE; KIDNEY CALCULI; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHOSPHORUS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNITED STATES; VITAMIN D;

EID: 84926609910     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07060714     Document Type: Article

References (49)

1. Lemann J Jr: Pathogenesis of idiopathic hypercalciuria and nephrolithiasis. In: Disorders of Bone and Mineral Metabolism, edited by Coe FL, Favus MJ, New York, Raven Press, 1992, pp 685-706
2. Coe F, Parks J, Evan A, Worcester E: Pathogenesis and treatment of nephrolithiasis. In: Seldin and Giebisch’s The Kidney, edited by Alpern R, Hebert SC, Academic Press, 2007, pp 1945-1977
3. Coe FL, Favus MJ, Crockett T, Strauss AL, Parks JH, Porat A, Gantt CL, Sherwood LM: Effects of low-calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 72: 25-32, 1982
4. Aloia JF, Patel M, Dimaano R, Li-Ng M, Talwar SA, Mikhail M, Pollack S, Yeh JK: Vitamin D intake to attain a desired serum 25-hydroxyvitaminDconcentration. AmJ ClinNutr 87: 1952-1958, 2008
5. Tjellesen L, Hummer L, Christiansen C, Rødbro P: Serum concentration of vitamin D metabolites during treatment with vitamin D2 and D3 in normal premenopausal women. Bone Miner 1: 407-413, 1986
6. Vieth R, Chan PC, MacFarlane GD: Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 73: 288-294, 2001
7. Dinour D, Beckerman P, Ganon L, Tordjman K, Eisenstein Z, Holtzman EJ: Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol 190: 552-557, 2013
8. Nesterova G, Malicdan MC, Yasuda K, Sakaki T, Vilboux T, Ciccone C, Horst R, Huang Y, Golas G, Introne W, Huizing M, Adams D, Boerkoel CF, Collins MT, Gahl WA: 1,25-(OH)2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin J Am Soc Nephrol 8: 649-657, 2013
9. Tebben PJ, Milliner DS, Horst RL, Harris PC, Singh RJ, Wu Y, Foreman JW, Chelminski PR, Kumar R Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: Effects of ketoconazole therapy. J Clin Endocrinol Metab 97: 423-427, 2012
10. Prie´ D, Ravery V, Boccon-Gibod L, Friedlander G: Frequency of renal phosphate leak among patients with calcium nephrolithiasis. Kidney Int 60: 272-276, 2001
11. Jaeger P, Portmann L, Ginalski JM, Jacquet AF, Temler E, Burckhardt P: Tubulopathy in nephrolithiasis: Consequence rather than cause. Kidney Int 29: 563-571, 1986
12. Lau YK, Wasserstein A, Westby GR, Bosanac P, Grabie M, Mitnick P, Slatopolsky E, Goldfarb S, Agus ZS: Proximal tubular defects in idiopathic hypercalciuria: Resistance to phosphate administration. Miner Electrolyte Metab 7: 237-249, 1982
13. Pabico RC, McKenna BA, Freeman RB: Renal threshold phosphate concentration in patients with idiopathic nephrolithiasis: Correlations with tubular functions, serum parathyroid hormone and 1,25 (OH)2D3. Proc Eur Dial Transplant Assoc 20: 450-454, 1983
14. Williams CP, Child DF, Hudson PR, Soysa LD, Davies GK, Davies MG, De Bolla AR: Inappropriate phosphate excretion in idiopathic hypercalciuria: The key to a common cause and future treatment? J Clin Pathol 49: 881-888, 1996
15. Worcester EM, Gillen DL, Evan AP, Parks JH, Wright K, Trumbore L, Nakagawa Y, Coe FL: Evidence that postprandial reduction of renal calcium reabsorption mediates hypercalciuria of patients with calcium nephrolithiasis. Am J Physiol Renal Physiol 292: 66-75, 2007
16. Rendina D, Esposito T, Mossetti G, De Filippo G, Gianfrancesco F, Perfetti A, Magliocca S, Formisano P, Prie´ D, Strazzullo P: A functional allelic variant of the FGF23 gene is associated with renal phosphate leak in calcium nephrolithiasis. J Clin Endocrinol Metab 97: E840-E844, 2012
17. Rendina D, Mossetti G, De Filippo G, Cioffi M, Strazzullo P: Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab 91: 959-963, 2006
18. Evan A, Lingeman J, Coe FL, Worcester E: Randall’s plaque: Pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int 69: 1313-1318, 2006
19. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, Sommer AJ, Paterson RF, Kuo RL, Grynpas M: Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest 111: 607-616, 2003
20. Miller NL, Gillen DL, Williams JC Jr, Evan AP, Bledsoe SB, Coe FL, Worcester EM, Matlaga BR, Munch LC, Lingeman JE: A formal test of the hypothesis that idiopathic calcium oxalate stones grow on Randall’s plaque. BJU Int 103: 966-971, 2009
21. Prentice RL, Breslow NE: Retrospective studies and failure time models. Biometrika 65: 153-158, 1978
22. Taylor EN, Curhan GC: Oxalate intake and the risk for nephrolithiasis. J Am Soc Nephrol 18: 2198-2204, 2007
23. Ascherio A, Rimm EB, Giovannucci EL, Colditz GA, Rosner B, Willett WC, Sacks F, Stampfer MJ: A prospective study of nutritional factors and hypertension among US men. Circulation 86: 1475-1484, 1992
24. Chasan-Taber S, Rimm EB, Stampfer MJ, Spiegelman D, Colditz GA, Giovannucci E, Ascherio A, Willett WC: Reproducibility and validity of a self-administered physical activity questionnaire for male health professionals. Epidemiology 7: 81-86, 1996
25. Giovannucci E, Colditz G, Stampfer MJ, Rimm EB, Litin L, Sampson L, Willett WC: The assessment of alcohol consumptionby a simple self-administered questionnaire.AmJ Epidemiol 133: 810-817, 1991
26. Hu FB, Leitzmann MF, Stampfer MJ, Colditz GA, Willett WC, Rimm EB: Physical activity and television watching in relation to risk for type 2 diabetes mellitus in men. Arch Intern Med 161: 1542-1548, 2001
27. Rimm EB, Stampfer MJ, Colditz GA, Chute CG, Litin LB, Willett WC: Validity of self-reported waist and hip circumferences in men and women. Epidemiology 1: 466-473, 1990
28. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC: Reproducibility and validity of an expanded selfadministered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol 135: 1114-1126, discussion 1127-1136, 1992
29. Willett W, Stampfer MJ: Total energy intake: Implications for epidemiologic analyses. Am J Epidemiol 124: 17-27, 1986
30. Willett WC: Nutritional Epidemiology, New York, Oxford University Press, 1998
31. Laha TJ, Strathmann FG, Wang Z, de Boer IH, Thummel KE, Hoofnagle AN: Characterizing antibody cross-reactivity for immunoaffinity purification of analytes prior to multiplexed liquid chromatography-tandem mass spectrometry. Clin Chem 58: 1711-1716, 2012
32. Taylor EN, Rimm EB, Stampfer MJ, Curhan GC: Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J 161: 956-962, 2011
33. Platz EA, Leitzmann MF, Hollis BW, Willett WC, Giovannucci E: Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15: 255-265, 2004
34. Worcester EM, Coe FL: New insights into the pathogenesis of idiopathic hypercalciuria. Semin Nephrol 28: 120-132, 2008
35. Adams ND, Gray RW, Lemann J Jr, Cheung HS: Effects of calcitriol administration on calcium metabolism healthy men. Kidney Int 21: 90-97, 1982
36. Maierhofer WJ, Gray RW, Cheung HS, Lemann J Jr: Bone resorption stimulated by elevated serum 1,25-(OH)2-vitamin D concentrations in healthy men. Kidney Int 24: 555-560, 1983
37. Asplin JR, Donahue S, Kinder J, Coe FL: Urine calcium excretion predicts bone loss in idiopathic hypercalciuria. Kidney Int 70: 1463-1467, 2006
38. Melton LJ 3rd, Crowson CS, Khosla S, Wilson DM, O’Fallon WM: Fracture risk among patients with urolithiasis: A populationbased cohort study. Kidney Int 53: 459-464, 1998
39. Jovanovich A, Buzkova P, Chonchol M, Robbins J, Fink HA, de Boer IH, Kestenbaum B, Katz R, Carbone L, Lee J, Laughlin GA, Mukamal KJ, Fried LF, Shlipak MG, Ix JH: Fibroblast growth factor 23, bone mineral density, and risk of hip fracture among older adults: The cardiovascular health study. J Clin Endocrinol Metab 98: 3323-3331, 2013
40. Lane NE, Parimi N, Corr M, Yao W, Cauley JA, Nielson CM, Ix JH, Kado D, Orwoll E; Osteoporotic Fractures in Men (MrOS) Study Group: Association of serum fibroblast growth factor 23 (FGF23) and incident fractures in older men: The Osteoporotic Fractures in Men (MrOS) study. J Bone Miner Res 28: 2325-2332, 2013
41. Mirza MA, Karlsson MK, Mellstrom D, Orwoll E, Ohlsson C, Ljunggren O, Larsson TE: Serum fibroblast growth factor-23 (FGF-23) and fracture risk in elderly men. J Bone Miner Res 26: 857-864, 2011
42. Gutierrez OM, Wolf M, Taylor EN: Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the Health Professionals Follow-Up Study. Clin J Am Soc Nephrol 6: 2871-2878, 2011
43. Tang J, McFann KK, Chonchol MB: Association between serum 25-hydroxyvitamin D and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988-94. Nephrol Dial Transplant 27: 4385-4389, 2012
44. Leaf DE, Korets R, Taylor EN, Tang J, Asplin JR, Goldfarb DS, Gupta M, Curhan GC: Effect of vitamin D repletion on urinary calcium excretion among kidney stone formers. Clin J Am Soc Nephrol 7: 829-834, 2012
45. Curhan GC, Willett WC, Speizer FE, Spiegelman D, Stampfer MJ: Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 126: 497-504, 1997
46. Curhan GC, Willett WC, Knight EL, Stampfer MJ: Dietary factors and the risk of incident kidney stones in younger women: Nurses’ Health Study II. Arch Intern Med 164: 885-891, 2004
47. Taylor EN, Curhan GC: Differences in 24-hour urine composition between black and white women. J Am Soc Nephrol 18: 654-659, 2007
48. Taylor EN, Stampfer MJ, Curhan GC: Dietary factors and the risk of incident kidney stones in men: New insights after 14 years of follow-up. J Am Soc Nephrol 15: 3225-3232, 2004
49. Taylor EN, Stampfer MJ, Curhan GC: Obesity, weight gain, and the risk of kidney stones. JAMA 293: 455-462, 2005